TransMedics reports 21% revenue growth in Q2 2026, raises 2026 revenue guidance amid strategic investments.

TransMedics Group reported a 21% increase in total revenue to $189.9 million for Q2 2026, driven by higher usage of its Organ Care System and logistics services. Despite a net income decline to $14.7 million due to increased operating expenses from strategic investments, the company raised its 2026 revenue guidance to $737-$757 million. TransMedics also completed a strategic investment in PAD Aviation to enhance organ transplant logistics in Europe. The company remains focused on expanding access and improving outcomes for organ transplant patients with its innovative technology and growth initiatives.